COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 4 of 757 for:    Phase II astrocytoma

Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas (AXL1717)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01721577
Recruitment Status : Unknown
Verified January 2015 by Robert Aiken, M.D., Rush University Medical Center.
Recruitment status was:  Recruiting
First Posted : November 4, 2012
Last Update Posted : January 12, 2015
Axelar AB
Information provided by (Responsible Party):
Robert Aiken, M.D., Rush University Medical Center